FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Veterinary medicine and science2022; 9(1); 150-157; doi: 10.1002/vms3.1034

Does lesion type or severity predict outcome of therapy for horses with equine glandular gastric disease? – A retrospective study.

Abstract: Equine glandular gastric disease (EGGD) is a common condition of the horse. Misoprostol is reported to be superior to oral omeprazole and sucralfate for treatment. Long-acting intramuscular injectable omeprazole (LAIOMEP) is a novel treatment shown to be effective in a small population. This study aimed to determine LAIOMEP efficacy compared to misoprostol and oral omeprazole and identify characteristics that predict treatment outcome. All horses that underwent gastroscopy between 2012 and 2019 were reviewed. Lesions were characterised by 4 blinded observers, all of whom are diplomates in equine internal medicine, using established descriptors from the ECEIM consensus statement and subjective severity. Treatment outcome was ranked as worsened, improved or healed. Consensus lesion type, lesion severity and treatment choice were compared to outcome and data screened using univariate analysis (chi-squared) to determine whether each predicted outcome. Lesion types where univariate analysis predicted a trend (p<0.2) were included in a multiple-regression analysis to identify predictors of outcome irrespective of treatment. Only severity significantly predicted final outcome (p = 0.025) with severe lesions being more likely to improve. Treatment choice did not significantly predict outcome. Overall healing rate was 29% (24 horses), and 43% (44 horses) improved. Treatment healing rates were 23% (10), 12% (7) and 27% (7) for LAIOMEP, misoprostol and oral omeprazole, respectively, with improvement in 69% (14), 76% (21) and 61% (9). 64% of the latter group received sucralfate. Worsening occurred in 7% (6). Treatment length varied with a median of 4 weeks (range 4-20 weeks). This study showed poorer therapy outcome compared to previous studies. The only initial lesion descriptor to predict outcome was severity and treatment choice did not affect outcome.
© 2022 The Authors. Veterinary Medicine and Science published by John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2022-12-10 PubMed ID: 36495212PubMed Central: PMC9857143DOI: 10.1002/vms3.1034Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigates whether the type or severity of lesions in horses with equine glandular gastric disease (EGGD) impacts the success of different treatments. The results show that only the severity of the lesions significantly predicts the outcome of the treatment, while the type of treatment used does not significantly affect the outcome.

Research Objectives and Methodology

  • The goal of the investigation was to measure the efficacy of a novel treatment, long-acting intramuscular injectable omeprazole (LAIOMEP), compared with misoprostol and oral omeprazole, which are common treatments for EGGD. The researchers also sought to identify specific characteristics that might predict the success of the different treatments.
  • The subjects of the study were horses that underwent gastroscopy procedures between 2012 and 2019. Four observers who specialize in equine internal medicine characterized the lesions and ranked the treatment outcomes as: worsened, improved, or healed.
  • The researchers conducted a univariate analysis to compare lesion types, severity, and treatment choices to the treatment outcomes. They identified lesion types predicted to trend using a multiple-regression analysis, but this data was found to be irrelevant to the treatment outcome.

Research Findings

  • With a significance level of p = 0.025 (indicating that the result is very likely true), the research found that only lesion severity significantly predicted the outcome of the treatment. Severe lesions were more likely to improve.
  • The choice of treatment did not significantly influence the outcome. The healing rates for LAIOMEP, misoprostol, and oral omeprazole were 23%, 12%, and 27% respectively, showing no significant difference in healing rates between the treatments.
  • Most horses (43%) improved, while a smaller number (29%) completely healed. A minimal number (7%) worsened. The median length of treatment was 4 weeks, but the range was quite wide (4 to 20 weeks).

Conclusion

  • The researchers found that the severity of the lesion was a significant factor in predicting treatment outcome, while the type of treatment administered to the horse did not show a significant effect on the outcome.
  • The findings differ from previous studies, which showed superior treatment outcomes. The authors suggest that the variability could be due to different definitions of ‘healing’ and ‘improvement,’ different protocols for assigning severity levels to lesions, or the potentially flawed assumption that ulcer scoring systems are linear.

Cite This Article

APA
Pratt SL, Bowen M, Hallowell GH, Shipman E, Bailey J, Redpath A. (2022). Does lesion type or severity predict outcome of therapy for horses with equine glandular gastric disease? – A retrospective study. Vet Med Sci, 9(1), 150-157. https://doi.org/10.1002/vms3.1034

Publication

Veterinary medicine and science
ISSN: 2053-1095
NlmUniqueID: 101678837
Country: England
Language: English
Volume: 9
Issue: 1
Pages: 150-157

Researcher Affiliations

Pratt, S L
  • School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonnington, UK.
Bowen, M
  • Medicine.vet, Upper Broughton, UK.
Hallowell, G H
  • IVC Evidensia, Keynsham, UK.
Shipman, E
  • School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonnington, UK.
Bailey, J
  • School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonnington, UK.
Redpath, A
  • School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonnington, UK.

MeSH Terms

  • Horses
  • Animals
  • Stomach Ulcer / veterinary
  • Retrospective Studies
  • Sucralfate
  • Misoprostol
  • Omeprazole / therapeutic use
  • Horse Diseases / drug therapy

Conflict of Interest Statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

References

This article includes 19 references
  1. Bowen M. Equine glandular gastric disease recommendations. Equine Health 2018, 29–33.
  2. Crumpton SM, Baiker K, Hallowell GD, Habershon-Butcher JL, Bowen IM. Clinical Research Abstracts of the British Equine Veterinary Association Congress 2015.. Equine Vet J 2015 Sep;47 Suppl 48:9.
    pubmed: 26374956doi: 10.1111/evj.12486_18google scholar: lookup
  3. Gough S, Hallowell G, Rendle D. Evaluation of the treatment of equine glandular gastric disease with either long-acting-injectable or oral omeprazole.. Vet Med Sci 2022 Mar;8(2):561-567.
    pmc: PMC8959258pubmed: 35167731doi: 10.1002/vms3.728google scholar: lookup
  4. Hepburn R, Proudman C. Treatment of ulceration of the gastric glandular mucosa: Retrospective evaluation of omeprazole and sucralfate combination therapy in 204 sport and leisure horses. Proceedings of the 11th International Equine Colic Research Symposium 2014.
  5. Powell C. The Delphi technique: myths and realities.. J Adv Nurs 2003 Feb;41(4):376-82.
    pubmed: 12581103doi: 10.1046/j.1365-2648.2003.02537.xgoogle scholar: lookup
  6. Pratt S, Bowen I, Hallowell G, Shipman E, Redpath A. Assessment of agreement using the equine glandular gastric disease grading system in 84 cases.. Vet Med Sci 2022 Jul;8(4):1472-1477.
    pmc: PMC9297748pubmed: 35412651doi: 10.1002/vms3.807google scholar: lookup
  7. Redpath A, Bowen M. Embracing the Cascade part 2: Clinical decision making in equine gastric disease. UK‐Vet Equine 3, 206–214.
  8. Rendle D, Bowen M, Brazil T, Conwell R, Hallowell G, Hepburn R, Hewetson M, Sykes B. Recommendations for the management of equine glandular gastric disease. UK‐Vet Equine 2, 2–11.
  9. Sykes BW, Hewetson M, Hepburn RJ, Luthersson N, Tamzali Y. European College of Equine Internal Medicine Consensus Statement--Equine Gastric Ulcer Syndrome in Adult Horses.. J Vet Intern Med 2015 Sep-Oct;29(5):1288-99.
    pmc: PMC4858038pubmed: 26340142doi: 10.1111/jvim.13578google scholar: lookup
  10. Sykes B, Jokisalo J. Rethinking equine gastric ulcer syndrome: Part 3 – Equine glandular gastric ulcer syndrome (EGGUS). Equine Veterinary Education 27, 372–375.
  11. Sykes BW, Kathawala K, Song Y, Garg S, Page SW, Underwood C, Mills PC. Preliminary investigations into a novel, long-acting, injectable, intramuscular formulation of omeprazole in the horse.. Equine Vet J 2017 Nov;49(6):795-801.
    pubmed: 28397996doi: 10.1111/evj.12688google scholar: lookup
  12. Sykes BW, Sykes KM, Hallowell GD. A comparison of two doses of omeprazole in the treatment of equine gastric ulcer syndrome: a blinded, randomised, clinical trial.. Equine Vet J 2014 Jul;46(4):416-21.
    pubmed: 24102898doi: 10.1111/evj.12191google scholar: lookup
  13. Sykes BW, Sykes KM, Hallowell GD. A comparison of two doses of omeprazole in the treatment of equine gastric ulcer syndrome: a blinded, randomised, clinical trial.. Equine Vet J 2014 Jul;46(4):416-21.
    pubmed: 24102898doi: 10.1111/evj.12191google scholar: lookup
  14. Sykes BW, Sykes KM, Hallowell GD. A comparison of three doses of omeprazole in the treatment of equine gastric ulcer syndrome: A blinded, randomised, dose-response clinical trial.. Equine Vet J 2015 May;47(3):285-90.
    pubmed: 24761780doi: 10.1111/evj.12287google scholar: lookup
  15. Sykes BW, Underwood C, Mills PC. The effects of dose and diet on the pharmacodynamics of esomeprazole in the horse.. Equine Vet J 2017 Sep;49(5):637-642.
    pubmed: 28117490doi: 10.1111/evj.12670google scholar: lookup
  16. Sykes BW, Bowen M, Habershon-Butcher JL, Green M, Hallowell GD. Management factors and clinical implications of glandular and squamous gastric disease in horses.. J Vet Intern Med 2019 Jan;33(1):233-240.
    pmc: PMC6335573pubmed: 30499188doi: 10.1111/jvim.15350google scholar: lookup
  17. Sykes BW, Sykes KM, Hallowell GD. Administration of trimethoprim-sulphadimidine does not improve healing of glandular gastric ulceration in horses receiving omeprazole: a randomised, blinded, clinical study.. BMC Vet Res 2014 Aug 23;10:180.
    pmc: PMC4445647pubmed: 25927827doi: 10.1186/s12917-014-0180-0google scholar: lookup
  18. Tallon R, Hewetson M. Inter-observer variability of two grading systems for equine glandular gastric disease.. Equine Vet J 2021 May;53(3):495-502.
    pubmed: 32808328doi: 10.1111/evj.13334google scholar: lookup
  19. Varley G, Bowen IM, Habershon-Butcher JL, Nicholls V, Hallowell GD. Misoprostol is superior to combined omeprazole-sucralfate for the treatment of equine gastric glandular disease.. Equine Vet J 2019 Sep;51(5):575-580.
    pubmed: 30809869doi: 10.1111/evj.13087google scholar: lookup

Citations

This article has been cited 1 times.
  1. Muñoz-Prieto A, Rubić I, Rešetar Maslov D, González-Sánchez JC, Mrljak V, Cerón JJ, Hansen S. Towards the Identification of New Biomarkers in Saliva and Serum for Treatment Monitoring of Equine Gastric Ulcer Syndrome: A Liquid Proteomic Approach. Animals (Basel) 2024 Oct 28;14(21).
    doi: 10.3390/ani14213105pubmed: 39518828google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.